Antibiotic prophylaxis in cirrhosis: Good and bad
Javier Fernández, Puneeta Tandon, Jose Mensa, Guadalupe Garcia‐Tsao – 3 November 2015 – Patients with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacterial infections that may further precipitate other liver decompensations including acute‐on‐chronic liver failure. Infections constitute the main cause of death in patients with advanced cirrhosis, and strategies to prevent them are essential.
The distribution of hepatitis B virus exposure and infection in a population‐based sample of U.S. Hispanic adults
Molly Jung, Mark H. Kuniholm, Gloria Y.F. Ho, Scott Cotler, Howard D. Strickler, Bharat Thyagarajan, Marston Youngblood, Robert C. Kaplan, Julia del Amo – 2 November 2015 – Little is known regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Latinos. We sought to determine the prevalence of HBV exposure (serum HBV core antibody; anti‐HBc), active HBV infection (serum HBV surface antigen; HBsAg), and vaccine‐induced HBV immunity (antibody against HBV surface antigen; anti‐HBs) in U.S.
Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome
Abhinav Vasudevan, Zaid Ardalan, Paul Gow, Peter Angus, Adam Testro – 2 November 2015
The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration
Giacomo Lanzoni, Vincenzo Cardinale, Guido Carpino – 2 November 2015 – Stem/progenitors for liver, biliary tree, and pancreas exist at early stages of development in the definitive ventral endoderm forming the foregut. In humans, they persist postnatally as part of a network, with evidence supporting their contributions to hepatic and pancreatic organogenesis throughout life. Multiple stem cell niches persist in specific anatomical locations within the human biliary tree and pancreatic ducts.
Reply
Marta Cavallin, Salvatore Piano, Paolo Angeli – 2 November 2015
Cost‐effectiveness of new antiviral regimens for treatment‐naïve U.S. veterans with hepatitis C
Alexis P. Chidi, Shari Rogal, Cindy L. Bryce, Michael J. Fine, Chester B. Good, Larissa Myaskovsky, Vinod K. Rustgi, Allan Tsung, Kenneth J. Smith – 2 November 2015 – Recently approved, interferon‐free medication regimens for treating hepatitis C are highly effective, but extremely costly. We aimed to identify cost‐effective strategies for managing treatment‐naïve U.S. veterans with new hepatitis C medication regimens. We developed a Markov model with 1‐year cycle length for a cohort of 60‐year‐old veterans with untreated genotype 1 hepatitis C seeking treatment in a typical year.
Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network
Robert S. Brown, Jacqueline G. O'Leary, K. Rajender Reddy, Alexander Kuo, Giuseppe J. Morelli, James R. Burton, R. Todd Stravitz, Christine Durand, Adrian M. Bisceglie, Paul Kwo, Catherine T. Frenette, Thomas G. Stewart, David R. Nelson, Michael W. Fried, Norah A. Terrault, on behalf of the Hepatitis C Therapeutic Registry Research Network Study Group – 31 October 2015 – Recurrent infection with the hepatitis C virus (HCV) after liver transplantation (LT) is associated with decreased graft and patient survival.
Clinical characteristics and outcomes of pyogenic vertebral osteomyelitis in patients with cirrhosis
Seong Yeon Park, Ki‐Ho Park, Oh‐Hyun Cho, Yu‐Mi Lee, Sang‐Ho Choi, Mi Suk Lee – 30 October 2015
Reply
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stal, Stergios Kechagias, Rolf Hultcrantz – 30 October 2015